Clinical Trials Logo

Clinical Trial Summary

Severe pancreatitis induces more damage in the pancreas and might therefore result reduced exocrine function leading to the insufficiency. The aim of this prospective study is to investigate development of pancreatic exocrine insufficiency in patients recovering from first attack of moderately severe or severe acute pancreatitis.


Clinical Trial Description

This is a prospective pilot study of 50 patients with first attack of moderately severe or severe acute pancreatitis (AP) classified by the new revised criteria for AP 2012 treated in Helsinki University Hospital. The included patients are treated according to the existing hospital practice and current guidelines for AP (American Pancreatic Association guidelines). The development of pancreatic exocrine insufficiency is determined by measuring the fecal elastase-1 test. The test is measured during the hospitalization time (baseline testing), and in the follow-up period 1-2 months and 12 months after discharging from hospital. The baseline test will be measured as soon as the severity of AP is known and patient is included in the study, and the first stool sample is available. Patients with previous history of AP, chronic pancreatitis, known pancreatic exocrine insufficiency or previous pancreatic surgery will be excluded. The patients' characteristics (age, gender, comorbidities) and etiology of AP, laboratory values on admission, imaging findings and data of given treatments and interventional therapies and length of hospital stays are collected from hospital charts. Also the 30-day and hospital mortality will be recorded. Patients' symptoms (weight loss, diarrhea, abdominal pain) and BMIs are recorded with physical examinations in the 1-2 months follow-up visit. 12 months after discharging from hospital the patients' symptoms and BMIs are recorded with phone inquiries. 5-year survival after the first AP attack will be determined from hospital records. The approval of the ethics committee of the hospital has been obtained. An informed consent will be obtained from all patients. Development of pancreatic exocrine insufficiency after first attack of moderately severe or severe AP confirmed by fecal elastase-1 test is the primary endpoint of this study. Also, the persistence pancreatic exocrine insufficiency and probable new developments of it during the follow-up will be assessed (secondary endpoints). 30-day and hospital mortality and 5-year survival after first attack of moderately severe or severe AP will be determined as well (secondary endpoints). The aim in this study (during the study period) is not to change the existing management of AP. The existing guidelines for treatment of severe AP patients do not include enzyme supplementation therapy. However, if the patients have low fecal elastase-1 levels indicating pancreatic exocrine insufficiency after the follow-up period of 12 months, they will be informed about the enzyme supplementation therapy. And if the patients are willing to start the therapy, it can be administrated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02563080
Study type Observational [Patient Registry]
Source Helsinki University Central Hospital
Contact
Status Completed
Phase
Start date September 2015
Completion date February 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05410795 - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Recruiting NCT04195347 - Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase Phase 1/Phase 2
Completed NCT04735055 - Artificial Intelligence Prediction for the Severity of Acute Pancreatitis
Completed NCT02928718 - The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
Terminated NCT02885441 - Treatment of Acute Pancreatitis With Ketorolac Phase 4
Recruiting NCT01626911 - Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis N/A
Completed NCT01507766 - The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Phase 4
Completed NCT04901949 - The Course of Acute Pancreatitis in Patients With Different BMI Groups
Recruiting NCT04814693 - Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis N/A
Completed NCT02743364 - Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis Phase 2
Recruiting NCT05281458 - Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections N/A
Not yet recruiting NCT04990336 - Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis N/A
Not yet recruiting NCT03259880 - Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals N/A
Completed NCT02543658 - Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension Phase 2
Recruiting NCT06023771 - Invasive Intervention of Local Complications of Acute Pancreatitis
Not yet recruiting NCT05501314 - Remote Home Monitoring Acute Pancreatitis N/A
Completed NCT02897206 - Imipenem Prophylaxis in Patients With Acute Pancreatitis Phase 4
Recruiting NCT03634787 - Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
Active, not recruiting NCT04989166 - Effect of Nano-curcumin Supplementation in Acute Pancreatitis N/A
Recruiting NCT05613673 - Prognostic Value of Different Nutritional Screening Tools in Acute Pancreatitis